



December 1, 2015

Dear Manufacturers

I am writing on behalf of NYU Lutheran Medical Center (340B ID#: DSH330306) to inform manufacturers that NYU Lutheran Medical Center recently underwent an audit by the Health Resources and Services Administration (HRSA) of the NYU Lutheran Medical Center's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, NYU Lutheran Medical Center qualified for the 340B Program as a DSH, in Brooklyn, New York and has participated in the program since 340B Program since October 1, 2004.

Through the audit process, HRSA found NYU Lutheran Medical Center to have non-compliance within its 340B Program and is responsible for repayment as a result of the following finding:

“(NYU Lutheran) did not have adequate controls in place to ensure proper accumulation and prevention of diversion of 340B drugs, as prohibited by section 340B(a)(5)(B) of the PHSA.”

NYU Lutheran Medical Center has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on repayment to affected manufacturers. If manufacturers have not received notification from NYU Lutheran Medical Center and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Steve DiCrescento, Director of Pharmacy, at (718) 630-7299 or 150 55th St, Brooklyn, NY 11220.

Sincerely,

A handwritten signature in black ink, appearing to read "Richard Langfelder", is written over a horizontal line.

Richard Langfelder  
Executive Vice President and Chief Financial Officer  
Authorizing Official